ALX Oncology Holdings is a clinical-stage immuno-oncology company that aims to develop therapies for cancer patients. The company's flagship product candidate, ALX148, is currently in Phase 1b/2 clinical trial for treating various cancers, including myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and solid tumors. ALX Oncology Holdings has established collaborations with Merck, Zymeworks, and Tallac Therapeutics, and was founded in 2015 and headquartered in South San Francisco, California.